• 1
    Cutler D. Are we finally winning the war on cancer? J Econ Perspect. 2008; 22: 3-26.
  • 2
    Ayanian JZ, Zaslavsky AM, Fuchs CS, et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol. 2003; 21: 1293-1300.
  • 3
    Bach PB, Cramer LD, Warren JL, Begg CB. Racial differences in the treatment of early-stage lung cancer. N Engl J Med. 1999; 341: 1198-1205.
  • 4
    Schrag D, Cramer LD, Bach PB, Begg CB. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst. 2001; 93: 850-857.
  • 5
    Keating NL, Landrum MB, Meara E, Ganz PA, Guadagnoli E. Do increases in the market share of managed care influence quality of cancer care in the fee-for-service sector? J Natl Cancer Inst. 2005; 97: 257-264.
  • 6
    Abraham NS, Gossey JT, Davila JA, Al-Oudat S, Kramer JK. Receipt of recommended therapy by patients with advanced colorectal cancer. Am J Gastroenterol. 2006; 101: 1320-1328.
  • 7
    Jackson GL, Melton LD, Abbott DH, et al. Quality of nonmetastatic colorectal cancer care in the Department of Veterans Affairs. J Clin Oncol. 2010; 28: 3176-3181.
  • 8
    Keating NL, Landrum MB, Lamont EB, et al. Quality of cancer care for older cancer patients in the Veterans Health Administration versus the private sector. Ann Intern Med. 2011; 154: 727-736.
  • 9
    Keating NL, Landrum MB, Klabunde CN, et al. Adjuvant chemotherapy for stage III colon cancer: do physicians agree about the importance of patient age and comorbidity? J Clin Oncol. 2008; 26: 2532-2537.
  • 10
    Rogers S, Gray S, Landrum MB, et al. Variations in surgeon treatment recommendations for lobectomy in early-stage non small cell lung cancer by patient age and comorbidity. Am J Surg Oncol. 2010; 17: 1581-1588.
  • 11
    Baldwin LM, Dobie SA, Billingsley K, et al. Explaining black-white differences in receipt of recommended colon cancer treatment. J Natl Cancer Inst. 2005; 97: 1211-1220.
  • 12
    Lathan CS, Neville BA, Earle CC. The effect of race on invasive staging and surgery in non-small-cell lung cancer. J Clin Oncol. 2006; 24: 413-418.
  • 13
    Morris AM, Billingsley KG, Hayanga AJ, Matthews B, Baldwin LM, Birkmeyer JD. Residual treatment disparities after oncology referral for rectal cancer. J Natl Cancer Inst. 2008; 100: 738-744.
  • 14
    Mahoney T, Kuo YH, Topilow A, Davis JM. Stage III colon cancers: why adjuvant chemotherapy is not offered to elderly patients. Arch Surg. 2000; 135: 182-185.
  • 15
    McCann J, Artinian V, Duhaime L, Lewis JWJr, Kvale PA, DiGiovine B. Evaluation of the causes for racial disparity in surgical treatment of early stage lung cancer. Chest. 2005; 128: 3440-3446.
  • 16
    Margolis ML, Christie JD, Silvestri GA, Kaiser L, Santiago S, Hansen-Flaschen J. Racial differences pertaining to a belief about lung cancer surgery: results of a multicenter survey. Ann Intern Med. 2003; 139: 558-563.
  • 17
    Cykert S, Dilworth-Anderson P, Monroe MH, et al. Factors associated with decisions to undergo surgery among patients with newly diagnosed early-stage lung cancer. JAMA. 2010; 303: 2368-2376.
  • 18
    Gordon HS, Street RLJr, Sharf BF, Kelly PA, Souchek J. Racial differences in trust and lung cancer patients' perceptions of physician communication. J Clin Oncol. 2006; 24: 904-909.
  • 19
    Gordon HS, Street RLJr, Sharf BF, Souchek J. Racial differences in doctors' information-giving and patients' participation. Cancer. 2006; 107: 1313-1320.
  • 20
    Cooper GS, Virnig B, Klabunde CN, Schussler N, Freeman J, Warren JL. Use of SEER-Medicare data for measuring cancer surgery. Med Care. 2002; 40( 8 suppl): IV-43- 48.
  • 21
    Lamont EB, Herndon JEJr, Weeks JC, et al. Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. J Natl Cancer Inst. 2005; 97: 1080-1083.
  • 22
    Lamont EB, Lauderdale DS, Schilsky RL, Christakis NA. Construct validity of Medicare chemotherapy claims: the case of 5FU. Med Care. 2002; 40: 201-211.
  • 23
    Virnig BA, Warren JL, Cooper GS, Klabunde CN, Schussler N, Freeman J. Studying radiation therapy using SEER-Medicare-linked data. Med Care. 2002; 40( 8 suppl): IV-49- 54.
  • 24
    NCCN colon cancer clinical practice guidelines in oncology. J Natl Compr Cancer Network. 2003; 1: 40-53.
  • 25
    NCCN rectal cancer clinical practice guidelines in oncology. J Natl Compr Cancer Network. 2003; 1: 54-63.
  • 26
    NCCN non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Cancer Network. 2006; 4: 548-582.
  • 27
    Piccirillo JF, Costas I, Claybour P, Borah AJ, Grove L, Jeffe D. The measurement of comorbidity by cancer registries. J Registry Manage. 2003; 30: 8-14.
  • 28
    Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001; 345: 1091-1097.
  • 29
    Kahn KL, Adams JL, Weeks JC, et al. Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA. 2010; 303: 1037-1045.
  • 30
    Battafarano RJ, Piccirillo JF, Meyers BF, et al. Impact of comorbidity on survival after surgical resection in patients with stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2002; 123: 280-287.